Aratana Therapeutics - PETX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.92
+0 (0.00%)
Get New Aratana Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PETX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PETX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aratana Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.92.

This chart shows the closing price for PETX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Aratana Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$4.76Low
4/26/2019HC WainwrightDowngradeBuy ➝ Neutral$5.00High
1/24/2019William BlairDowngradeOutperform ➝ Market Perform$4.14Medium
1/11/2019Stifel NicolausDowngradeBuy ➝ Hold$8.00 ➝ $5.00High
11/5/2018HC WainwrightSet TargetBuy$10.00Medium
8/6/2018Stifel NicolausLower TargetBuy ➝ Buy$8.00 ➝ $7.00High
5/7/2018HC WainwrightSet TargetBuy$10.00Medium
3/27/2018Stifel NicolausUpgradeHold ➝ Buy$6.00 ➝ $8.00High
3/19/2018HC WainwrightSet TargetBuy$10.00Low
3/16/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$9.00 ➝ $8.00Low
3/12/2018CL KingUpgradeNeutral ➝ Buy$8.00High
1/16/2018HC WainwrightSet TargetBuy$10.00High
12/27/2017CL KingInitiated CoverageNeutral ➝ NeutralLow
12/21/2017HC WainwrightSet TargetBuy$10.00Low
12/18/2017Stifel NicolausReiterated RatingHold$6.00High
(Data available from 12/7/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Aratana Therapeutics logo
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Read More

Today's Range

Now: $4.92
Low: $4.92
High: $4.92

50 Day Range

MA: $4.92
Low: $4.92
High: $4.92

52 Week Range

Now: $4.92
Low: $3.30
High: $7.16

Volume

N/A

Average Volume

1,030,946 shs

Market Capitalization

$241.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Aratana Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Aratana Therapeutics in the last year:
View the latest analyst ratings for PETX.

What is the current price target for Aratana Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aratana Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aratana Therapeutics in the next year.
View the latest price targets for PETX.

What is the current consensus analyst rating for Aratana Therapeutics?

Aratana Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PETX.

What other companies compete with Aratana Therapeutics?

How do I contact Aratana Therapeutics' investor relations team?

Aratana Therapeutics' physical mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company's listed phone number is 913-353-1000 and its investor relations email address is [email protected] The official website for Aratana Therapeutics is www.aratana.com. Learn More about contacing Aratana Therapeutics investor relations.